Protagonist Reports Second Quarter 2017 Financial Results And Business Highlights
NEWARK, Calif., Aug. 8, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the second quarter and six months ended June 30, 2017.
"Protagonist achieved several significant milestones during the second quarter, most notably the signing of a major license and collaboration agreement with Janssen for PTG-200, our pre-clinical stage oral interleukin-23 receptor (IL-23R) antagonist for inflammatory bowel diseases (IBD)," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics. "In addition to the strategic advantages this major partnership provides us, it has also extended our financial runway, enabling us to advance our clinical pipeline of innovative peptide drugs and expand the utility of our technology platform."
"Protagonist achieved several significant milestones during the second quarter, most notably the signing of a major license and collaboration agreement with Janssen for PTG-200, our pre-clinical stage oral interleukin-23 receptor (IL-23R) antagonist for inflammatory bowel diseases (IBD)," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics. "In addition to the strategic advantages this major partnership provides us, it has also extended our financial runway, enabling us to advance our clinical pipeline of innovative peptide drugs and expand the utility of our technology platform."